Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd + Azeliragon in T-DXd-Resistant HER2+ or HER2-Low Metastatic Breast Cancer
NCT07785856Phase 2Not yet recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Dec 2026
- Primary completion
- Dec 2028
01
Overview
Phase 2, open-label, single-arm trial of azeliragon in breast cancer, sponsored by Houston Methodist Research Institute. Primary endpoints: Recommended Phase II Dose at 3 weeks and Objective Response Rate up to 2 years. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
azeliragon
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07785856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07785856.